The COntAGIouS trial (COvid-19 Advanced Genetic and Immunologic Sampling; an in-depth characterization of the dynamic host immune response to coronavirus SARS-CoV-2) proposes a transdisciplinary approach to identify host factors resulting in hyper-susceptibility to SARS-CoV-2 infection, which is urgently needed for directed medical interventions.
The overall aim of this prospective study is to provide an in-depth characterization of
clinical and immunological features of patients hospitalized in UZ Leuven because of
SARS-CoV-2 infection. For this purpose, clinical data and blood, nasopharyngeal/rectal swab,
and if safe, bronchoalveolar lavage (BAL) fluid and lung tissue samples will be collected
from PCR- or CT-confirmed COVID-19 patients, with varying degrees of disease severity.
Assessed characteristics will be compared between severe and non-severe COVID-19 patients,
and between COVID-19 positive and negative ('control') patients.
Other: Patient sampling
Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable
Inclusion Criteria:
- Patients >/= 18 years old AND
- Hospitalised with PCR-confirmed and/or CT-confirmed SARS-CoV-2 disease
Exclusion Criteria:
- Age < 18 years old
- No informed consent
UZ Leuven
Leuven, Belgium
Investigator: Joost Wauters, MD PhD
Joost Wauters, MD PhD
003216344275
joost.wauters@uzleuven.com
Joost Wauters, MD PhD, Principal Investigator
UZ Leuven